220634-41-3Relevant articles and documents
CHROMANE DERIVATIVES AS TRPV3 MODULATORS
-
Page/Page column 10; 13, (2010/12/29)
The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are pro
Synthesis and activity on rat aorta rings and rat pancreatic β-cells of ring-opened analogues of benzopyran-type potassium channel activators
Khelili, Smail,Florence, Xavier,Bouhadja, Mourad,Abdelaziz, Samia,Mechouch, Nadia,Mohamed, Yekhlef,de Tullio, Pascal,Lebrun, Philippe,Pirotte, Bernard
, p. 6124 - 6130 (2008/12/21)
Ring-opened analogues of dihydrobenzopyran potassium channel openers (PCOs) were prepared and evaluated as putative PCOs on rat aorta rings (myorelaxant effect) and rat pancreatic β-cells (inhibition of insulin secretion). These derivatives are characterized by the presence of a sulfonylurea, a urea or an amide function. Some compounds bearing an arylurea moiety provoked vasorelaxant effects and a marked inhibition of insulin release. Derivatives bearing a sulfonylurea or an amide function were, however, poorly active on both tissues. Structure-activity relationships and apparent tissue selectivity are discussed.
ISOQUINOLINE DERIVATIVES AS VANILLOID RECEPTOR MODULATORS
-
Page/Page column 25, (2008/12/05)
The present invention relates to substituted isoquinoline derivatives of formula I, which can be used as vanilloid receptor ligands, methods of treating diseases, condition and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.
PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION
-
Page/Page column 123, (2010/11/24)
The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas ( I ) and ( II ).
1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use
-
Page/Page column 40, (2010/02/15)
Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and
Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
-
Page/Page column 41, (2008/06/13)
Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.